HCG and HGH Interaction: Monitor | Peptide Database

Join others researching DNSP-11 — share findings, ask questions, and learn from real experiences DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health. DNSP-11 acts on dopaminergic neurons through mechanisms distinct from full-length GDNF. Rather than binding to the canonical GFRalpha1/RET receptor complex, DNSP-11 appears to engage alternative signaling pathways to promote dopaminergic neuron survival, stimulate dopamine release, and protect against neurotoxin-induced damage. It enhances tyrosine hydroxylase expression (the rate-limiting enzyme in dopamine synthesis) and supports mitochondrial function in dopaminergic neurons.

RAD-140 has shown potent anabolic effects on skeletal muscle in preclinical models, with increases in lean body mass comparable to moderate doses of testosterone. Users report meaningful increases in lean mass over 8-12 week cycles at 10-20 mg/day, though controlled human trial data for this indication is lacking. Dose-dependent increases in strength have been reported anecdotally and are consistent with the compound's mechanism of action as a potent AR agonist in skeletal muscle. Strength gains are typically noticed within 2-4 weeks of starting a cycle. The combination of anabolic activity without estrogenic water retention makes RAD-140 a compound of interest for simultaneous fat loss and lean mass gain. Preclinical data supports a favorable shift in body composition, though human data is limited. RAD-140 has entered Phase 1 clinical trials for the treatment of ER+/AR+/HER2- metastatic breast cancer. The rationale is that AR activation can suppress estrogen-driven tumor growth in AR-positive breast cancers. Early results demonstrated tolerability and preliminary signals of anti-tumor activity. Originally developed for conditions involving muscle wasting (cachexia, sarcopenia, age-related muscle loss). Preclinical data supports the potential to preserve or restore muscle mass in catabolic states, but no human efficacy trials have been completed for this indication. In vitro studies have shown that RAD-140 protects hippocampal neurons from kainate-induced excitotoxicity and beta-amyloid-induced cell death, suggesting potential relevance to neurodegenerative diseases. This remains a preclinical observation only.